MedPharm and Tergus Pharma, have merged to create a novel contract development and manufacturing organisation (CDMO) that specifically focuses on the end-to-end development and commercialisation of topical and transepithelial pharmaceuticals.
The organisation will operate under the MedPharm name, and will focus on scientific and clinical trial manufacturing, as well as commercial production for the wider pharmaceutical market.
To complement this merger, CEO of Tergus Pharma, Michael Kane has been appointed as CEO of MedPharm while Patrick Walsh continues to serve as an Executive Chairperson for MedPharm.
Bringing expertise together
The strategic merger allows the companies to combine their areas of expertise, allowing them to enhance their commercial production, serialisation, in vitro testing, clinical manufacturing and existing formulation development capabilities.
The novel CDMO will also be able to develop and manufacture hormone-based, high-potency drugs at their Durham, North Carolina GMP manufacturing facility.
Michael Kane commented: “This strategic partnership is an exciting opportunity to deliver extensive pharmaceutical product development resources fuelled by a robust team of scientific experts. With locations in both the UK and the US, we are well positioned to provide support to our existing and prospective pharmaceutical clients.”
MedPharm Executive Chairperson Patrick Walsh added: “Pharma clients have been seeking a reliable, integrated service offering for their ophthalmic, topical, and transdermal development and manufacturing projects. This merger creates an immediate option with two organisations already well-positioned in the industry.”
[Photo credit: MedPharm]
